Menu

HomeConferencesCollectionsCalls for PapersMSF Research EthicsAboutMy Saved Content
Logo

Science Portal

  • My Saved Content
  • Browse All
  • Conferences
  • Collections
  • Calls for Papers
  • MSF Research Ethics
  • Clinical Case Reporting
  • About
English
logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.6118.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.6118.produseast1
Conference Material
|Slide Presentation

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer KKD, Alcoba G, Muthoni Ouattara G, Egondi T, Nakanwagi P, Omollo T, Wasunna M, Alvar J,
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial | Conference Material / Slide Presentation | MSF Science Portal
Alves F
Download
Similar Content
Abstract
|Abstract
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Video
|Video
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Loading...

Countries

Ethiopia Kenya Uganda Sudan

Subject Area

pediatricsneglected tropical diseaseskala azarleishmaniasis

Languages

English
DOI
10.57740/81jj-tz57
Published Date
07 Jun 2023
Conference
MSF Scientific Day International 2023
Linked Content
Conference Material
|Abstract
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Conference Material
|Video
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023